☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
approva
Merck's Keytruda (pembrolizumab) + Inlyta (axitinib) Receive FDA's Approval as 1L Treatment for Advanced Renal Cell Carcinoma
April 22, 2019
Load more...
Back to Home